Class 4

Class 4 Medicines Defect Information: Quadrant Pharmaceuticals Limited, Bezalip Mono 400mg Tablets, EL (22)A/38

Quadrant Pharmaceuticals Limited have informed the MHRA of an error with the Patient Information Leaflets (PILs) that have been packaged in various parallel imported batches.

MDR Number: MDR 025-09/22

Company name: Quadrant Pharmaceuticals Limited

Product description: Bezalip Mono 400mg Tablets PLPI 20774/0036

Details of the affected batch:

Batch Number

Expiry Date

Pack Size

First Distributed

J3594

09/2025

30

17/11/2021

J3741

09/2025

30

30/11/2021

J3943

09/2025

30

15/12/2021

K0077

01/2026

30

25/01/2022

K0310

01/2026

30

08/02/2022

K0327

12/2025

30

10/02/2022

K0455

09/2025

30

11/02/2022

K0547

12/2025

30

22/02/2022

K0549

09/2025

30

22/02/2022

K0562

01/2026

30

23/02/2022

K2019

01/2027

30

10/06/2022

K1994

01/2027

30

17/06/2022

K2196

01/2027

30

01/07/2022

K2274

10/2026

30

06/07/2022

K2742

01/2027

30

26/07/2022

K2943

01/2027

30

18/08/2022

K3158

01/2027

30

24/08/2022

K3134

01/2027

30

30/08/2022

Active Pharmaceutical Ingredient: bezafibrate

Brief description of problem:

Quadrant Pharmaceuticals Limited have informed the MHRA of an error with the Patient Information Leaflets (PILs) that have been packaged in the above parallel imported batches. The PIL included in the batches above is an older version of the PIL, which does not include the most up to date safety information.

The information missing from the PILs are as below:

Section 4. Possible side effects

Contact your doctor immediately if you notice signs of:

  • severe form of skin rash with flushing, fever, blisters or ulcers (Stevens-Johnson Syndrome)
  • severe rash involving reddening, peeling and swelling of the skin that resembles severe burns (Toxic epidermal necrolysis).

 

Advice to Healthcare Professionals:

There is no risk to product quality as a result of this issue, therefore the affected batches are not being recalled. Healthcare professionals are advised to discuss the missing information with patients and provide a copy of the updated PIL, where appropriate. MHRA PIL Link: Bezalip Mono 400mg Tablets PLPI 20774/0036.

Quadrant Pharmaceuticals Limited have confirmed that no further units of any of the above batches will be released, therefore this notification only applies to packs that are already at pharmacy or wholesaler level, or in the possession of patients.

Quadrant Pharmaceuticals Limited have also confirmed that all future batches will contain the updated PIL and that upon request they will send hard copies by post of the updated PIL to wholesalers and pharmacies, so that any remaining stock in the dispensary can be supplemented with the updated PIL information.

 

Advice to Patients:

Patients should be aware that the Patient Information Leaflet (PIL) in the above batches does not contain the most up to date safety information on skin side effects.

If you experience any of the side effects listed below, you should contact your doctor immediately:

  • severe form of skin rash with flushing, fever, blisters or ulcers
  • severe rash involving reddening, peeling and swelling of the skin that resembles severe burns

If you have any questions about your medicine or are concerned about side effects, talk to your healthcare professional.

The medicine itself is not affected and any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

 

Company contacts for further information:

For more information, medical or supply enquiries, please contact radoslaw.bandomir@maxearn.co.uk or natalie.harrison@hallohealthcaregroup.com

To access the full recall:

Class 4 Medicines Defect Information: Quadrant Pharmaceuticals Limited, Bezalip Mono 400mg Tablets, EL (22)A/38